Golden has been acquired by ComplyAdvantage.Read about it here ⟶

List of Nps Pharmaceuticals patents

Patents where

Current Assignee

Name

Nps Pharmaceuticals

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 7888317 Glucagon-like peptide-2 and its therapeutic use	Patent 7888317 was granted and assigned to Nps Pharmaceuticals on February, 2011 by the United States Patent and Trademark Office.		Nps Pharmaceuticals	United States Patent and Trademark Office	7888317	February 15, 2011
‌ US Patent 7473537 Cloned glucagon-like peptide-2 receptors	Patent 7473537 was granted and assigned to Nps Pharmaceuticals on January, 2009 by the United States Patent and Trademark Office.		Nps Pharmaceuticals	United States Patent and Trademark Office	7473537	January 6, 2009
‌ US Patent 9060992 Treatment of short bowel syndrome patients with colon-in-continuity	Patent 9060992 was granted and assigned to Nps Pharmaceuticals on June, 2015 by the United States Patent and Trademark Office.		Nps Pharmaceuticals	United States Patent and Trademark Office	9060992	June 23, 2015
‌ US Patent 9545434 Treatment of short bowel syndrome patients with colon-in-continuity	Patent 9545434 was granted and assigned to Nps Pharmaceuticals on January, 2017 by the United States Patent and Trademark Office.	Nps Pharmaceuticals	Nps Pharmaceuticals	United States Patent and Trademark Office	9545434	January 17, 2017
‌ US Patent 7847061 Treatment of short bowel syndrome patients with colon-in-continuity	Patent 7847061 was granted and assigned to Nps Pharmaceuticals on December, 2010 by the United States Patent and Trademark Office.		Nps Pharmaceuticals	United States Patent and Trademark Office	7847061	December 7, 2010
‌ US Patent 9555079 Treatment of short bowel syndrome patients with colon-in-continuity	Patent 9555079 was granted and assigned to Nps Pharmaceuticals on January, 2017 by the United States Patent and Trademark Office.	Nps Pharmaceuticals	Nps Pharmaceuticals	United States Patent and Trademark Office	9555079	January 31, 2017
‌ US Patent 7708732 Methods of administering therapeutic injections	Patent 7708732 was granted and assigned to Nps Pharmaceuticals on May, 2010 by the United States Patent and Trademark Office.		Nps Pharmaceuticals	United States Patent and Trademark Office	7708732	May 4, 2010
‌ US Patent 8148508 Method for enzymatic production of GLP-2(1-33) and GLP-2(1-34) peptides	Patent 8148508 was granted and assigned to Nps Pharmaceuticals on April, 2012 by the United States Patent and Trademark Office.		Nps Pharmaceuticals	United States Patent and Trademark Office	8148508	April 3, 2012
‌ US Patent 7829307 Production of glucagon-like peptide 2	Patent 7829307 was granted and assigned to Nps Pharmaceuticals on November, 2010 by the United States Patent and Trademark Office.		Nps Pharmaceuticals	United States Patent and Trademark Office	7829307	November 9, 2010
‌ US Patent 7749543 Methods useful in the treatment of bone resorption diseases	Patent 7749543 was granted and assigned to Nps Pharmaceuticals on July, 2010 by the United States Patent and Trademark Office.		Nps Pharmaceuticals	United States Patent and Trademark Office	7749543	July 6, 2010
‌ US Patent 7781401 Glucagon-like peptide-2 analogs	Patent 7781401 was granted and assigned to Nps Pharmaceuticals on August, 2010 by the United States Patent and Trademark Office.		Nps Pharmaceuticals	United States Patent and Trademark Office	7781401	August 24, 2010
‌ US Patent 8450336 Use of D-serine derivatives for the treatment of anxiety disorders	Patent 8450336 was granted and assigned to Nps Pharmaceuticals on May, 2013 by the United States Patent and Trademark Office.		Nps Pharmaceuticals	United States Patent and Trademark Office	8450336	May 28, 2013
‌ US Patent 7642241 Methods of enhancing functioning of the large intestine	Patent 7642241 was granted and assigned to Nps Pharmaceuticals on January, 2010 by the United States Patent and Trademark Office.		Nps Pharmaceuticals	United States Patent and Trademark Office	7642241	January 5, 2010
‌ US Patent 8980567 Ex vivo method for determining potential GLP-2 receptor modulators	Patent 8980567 was granted and assigned to Nps Pharmaceuticals on March, 2015 by the United States Patent and Trademark Office.	Nps Pharmaceuticals	Nps Pharmaceuticals	United States Patent and Trademark Office	8980567	March 17, 2015
‌ US Patent 9545435 Treatment of short bowel syndrome patients with colon-in-continuity	Patent 9545435 was granted and assigned to Nps Pharmaceuticals on January, 2017 by the United States Patent and Trademark Office.	Nps Pharmaceuticals	Nps Pharmaceuticals	United States Patent and Trademark Office	9545435	January 17, 2017
‌ US Patent 7977061 Ex vivo method for determining potential GLP-2 receptor modulators	Patent 7977061 was granted and assigned to Nps Pharmaceuticals on July, 2011 by the United States Patent and Trademark Office.		Nps Pharmaceuticals	United States Patent and Trademark Office	7977061	July 12, 2011
‌ US Patent 8257983 Ex vivo method for determining potential GLP-2 receptor modulators	Patent 8257983 was granted and assigned to Nps Pharmaceuticals on September, 2012 by the United States Patent and Trademark Office.		Nps Pharmaceuticals	United States Patent and Trademark Office	8257983	September 4, 2012
‌ US Patent 9539310 Treatment of short bowel syndrome patients with colon-in-continuity	Patent 9539310 was granted and assigned to Nps Pharmaceuticals on January, 2017 by the United States Patent and Trademark Office.	Nps Pharmaceuticals	Nps Pharmaceuticals	United States Patent and Trademark Office	9539310	January 10, 2017
‌ US Patent 8481276 Ex vivo method for determining potential GLP-2 receptor modulators	Patent 8481276 was granted and assigned to Nps Pharmaceuticals on July, 2013 by the United States Patent and Trademark Office.		Nps Pharmaceuticals	United States Patent and Trademark Office	8481276	July 9, 2013
‌ US Patent 8765674 Methods useful in the treatment of bone resorption diseases	Patent 8765674 was granted and assigned to Nps Pharmaceuticals on July, 2014 by the United States Patent and Trademark Office.		Nps Pharmaceuticals	United States Patent and Trademark Office	8765674	July 1, 2014
‌ US Patent 7781567 Method for enzymatic production of GLP-2(1-33) and GLP-2(1-34) peptides	Patent 7781567 was granted and assigned to Nps Pharmaceuticals on August, 2010 by the United States Patent and Trademark Office.		Nps Pharmaceuticals	United States Patent and Trademark Office	7781567	August 24, 2010
‌ US Patent 7816408 Calcium receptor active compounds	Patent 7816408 was granted and assigned to Nps Pharmaceuticals on October, 2010 by the United States Patent and Trademark Office.		Nps Pharmaceuticals	United States Patent and Trademark Office	7816408	October 19, 2010
‌ US Patent 7498141 Assay system for GLP-2 receptor ligands	Patent 7498141 was granted and assigned to Nps Pharmaceuticals on March, 2009 by the United States Patent and Trademark Office.		Nps Pharmaceuticals	United States Patent and Trademark Office	7498141	March 3, 2009
‌ US Patent 7902401 Fluorinated compounds	Patent 7902401 was granted and assigned to Nps Pharmaceuticals on March, 2011 by the United States Patent and Trademark Office.		Nps Pharmaceuticals	United States Patent and Trademark Office	7902401	March 8, 2011
‌ US Patent 9782455 Solid phase synthesis of h(Gly2)GLP-2	Patent 9782455 was granted and assigned to Nps Pharmaceuticals on October, 2017 by the United States Patent and Trademark Office.		Nps Pharmaceuticals	United States Patent and Trademark Office	9782455	October 10, 2017

Results per page:

28 results

0 selected

28 results

0 selected